According to a new study published in The Oncologist, patients with advanced cancer who are diagnosed with delirium when turning up in emergency departments are more likely to be admitted to hospital and more likely to die earlier than patients without delirium. This shows the importance of accurately diagnosing delirium in advanced cancer patients, says lead author Ahmed Elsayem at the University of Texas MD Anderson Cancer Center in Houston, TX, even though delirium can easily be missed in busy emergency departments.
In patients with advanced cancer, delirium can be caused by various different factors. "Advanced cancer itself is a major cause, and other problems such as medications or infection are triggers that can precipitate the full blown syndrome," explains Elsayem. Previous studies have shown that delirium is associated with poor survival in advanced cancer patients being treated in intensive care units (ICUs) or receiving palliative care in hospices, but no one had investigated whether the same was true for those reporting to emergency departments.
"To the best our knowledge this is the first study to show the poor survival of advanced cancer patients in the emergency department setting," says Elsayem.
This study follows on from an earlier study conducted by Elsayem and his colleagues in which they assessed the frequency of delirium in advanced cancer patients visiting the emergency department at MD Anderson. They tested for delirium using two separate questionnaires, classifying patients as suffering from delirium if at least one of the questionnaires gave a positive result.
Questioning 243 patients in total, they found that 44, or 18%, were suffering with delirium according to at least one of the questionnaires. In this current study, they investigated the proportion of these cancer patients with and without delirium that were subsequently admitted to hospital and ICUs, and recorded how long they lived after their visit to the emergency department. They also looked at whether possessing advanced directives, which specify the treatments a patient wants to receive if they are no longer able to make decisions for themselves, influenced the rates of hospitalization and survival.
They discovered that the majority of cancer patients with delirium were admitted to hospital (80%), whereas only 49% of those without delirium were admitted; patients with delirium were also much more likely to be admitted into the ICU. Advanced cancer patients with delirium were also likely to die earlier, surviving for a median time of between one and four months after their visit to the emergency department, compared with a median survival time of over 10 months for patients without delirium. Although around half of the patients had advanced directives, these did not seem to have any effect on the rates of hospitalization or survival.
Given the major influence delirium appears to have on survival, as well as the distress it can cause for patients and their family members, Elsayem says that prompt diagnosis and management in hospital emergency departments is essential. Especially as, in many cases, delirium in advanced cancer patients can be resolved by simply stopping or modifying their medication and treating any associated infections. "Treating the triggers if known – such as stopping medications – is the main treatment for an episode of delirium," says Elsayem.
He also suggests that further research needs to be done on this topic, including conducting similar studies on delirium in advanced cancer patients in other emergency departments and with larger groups of patients.
"This prospective cross-sectional study of patients with advanced cancer provides new information about the identification of delirium in the emergency department," said Russell Portenoy, executive director of the MJHS Institute for Innovation in Palliative Care, NY, who is a section editor of The Oncologist and was not involved in the study. "The key findings – that delirium is a poor prognostic sign and that many patients who present with delirium lack advance directives – underscore the need for competent assessment to identify delirium and follow this diagnosis with a plan of care informed by the increased risk of mortality. Importantly, presentation with delirium in the emergency department should trigger evaluation of advance directives, which, if lacking, can be obtained or refined if capacity is present or restored by treatment of the delirium.
Full citation: "Advance Directives, Hospitalization, and Survival among Advanced Cancer Patients with Delirium Presenting to The Emergency Department: a Prospective Study." Ahmed F. Elsayem, Eduardo Bruera, Alan Valentine, Carla L. Warneke, Geri L. Wood, Sai-Ching J. Yeung, Valda D. Page, Julio Silvestre, Patricia A. Brock, Knox H. Todd. The Oncologist. Published Online: August 1, 2017; DOI: 10.1634/theoncologist.2017-0115.
URL Upon Publication: http://dx.doi.org/10.1634/theoncologist.2017-0115
Author Contact: To arrange an interview with the author, please contact Julie Penne at MD Anderson Public Relations ([email protected]; +1 713-792-0662).
About The Oncologist
Now celebrating its 22nd edition, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. The Oncologist is the official journal of the Society for Translational Oncology (STO).
About AlphaMed Press Established in 1983, AlphaMed Press, which has offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, is the publisher of three internationally renowned peer-reviewed journals. The Oncologist®, which is entering its 20th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS®, celebrating its 35th year, is the world's first journal devoted to this fast paced field of research. STEM CELLS Translational Medicine®, currently in its sixth year, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.